Your browser doesn't support javascript.
loading
Long-Term Follow-Up of Tufting Enteropathy Caused by EPCAM Mutation p.Asp253Asn and Absent EPCAM Expression.
Ozler, Oguz; Brunner-Véber, Andrea; Fatih, Parmis; Müller, Thomas; Janecke, Andreas R; Arikan, Cigdem.
Afiliação
  • Ozler O; From the Koc University School of Medicine, Pediatric Gastroenterology and Hepatology, Organ Transplantation and Research Center, Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey.
  • Brunner-Véber A; Institut für Pathologie, Neuropathologie und Molekularpathologie, Medical University of Innsbruck, Innsbruck, Austria.
  • Fatih P; From the Koc University School of Medicine, Pediatric Gastroenterology and Hepatology, Organ Transplantation and Research Center, Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey.
  • Müller T; Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
  • Janecke AR; Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
  • Arikan C; Division of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
JPGN Rep ; 2(1): e029, 2021 Feb.
Article em En | MEDLINE | ID: mdl-37206930
Tufting enteropathy (TE) is caused by recessive epithelial cell adhesion molecule (EPCAM) mutations, features congenital intractable diarrhea, growth retardation, and a characteristic disorganization of surface enterocytes. TE generally requires parenteral nutrition (PN) throughout childhood and into adulthood or a small bowel transplantation. We report 2 siblings with TE; a 3-year-old patient 1 intermittently receives partial PN, monthly somatostatin therapy, tolerates a normal diet and has a normal stool output. However, she is the sixth patient of 90 TE patients in literature, to develop a chronic arthritis. A 12-year-old patient 2 is on a normal diet, and did not require PN for the past 8 years. Duodenal biopsies showed characteristic tufts, and a complete lack of EPCAM staining. Both siblings were homozygous for EPCAM mutation c.757G>A (p.Asp253Asn). This observation shows that an overall favorable outcome can be obtained in TE, even with abrogated intestinal EPCAM expression.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article